References
- Olanow CW and Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22, 123-144 https://doi.org/10.1146/annurev.neuro.22.1.123
- Dauer W and Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909 https://doi.org/10.1016/S0896-6273(03)00568-3
- Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 https://doi.org/10.1126/science.276.5321.2045
- Singleton AB, Farrer M, Johnson J et al (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 https://doi.org/10.1126/science.1090278
- Chartier-Harlin MC, Kachergus J, Roumier C et al (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169 https://doi.org/10.1016/S0140-6736(04)17103-1
- Lee VM and Trojanowski JQ (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33-38 https://doi.org/10.1016/j.neuron.2006.09.026
- Fujiwara H, Hasegawa M, Dohmae N et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4, 160-164 https://doi.org/10.1038/ncb748
- Jackson-Lewis V, Blesa J and Przedborski S (2012) Animal models of Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1, S183-185 https://doi.org/10.1016/S1353-8020(11)70057-8
- Koprich JB, Kalia LV and Brotchie JM (2017) Animal models of alpha-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci 18, 515-529 https://doi.org/10.1038/nrn.2017.75
- Brennand KJ, Simone A, Jou J et al (2011) Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225 https://doi.org/10.1038/nature09915
- Dimos JT, Rodolfa KT, Niakan KK et al (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218-1221 https://doi.org/10.1126/science.1158799
- Laflamme MA, Chen KY, Naumova AV et al (2007) Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25, 1015-1024 https://doi.org/10.1038/nbt1327
- Li XJ, Du ZW, Zarnowska ED et al (2005) Specification of motoneurons from human embryonic stem cells. Nat Biotechnol 23, 215-221 https://doi.org/10.1038/nbt1063
- Maroof AM, Brown K, Shi SH, Studer L and Anderson SA (2010) Prospective isolation of cortical interneuron precursors from mouse embryonic stem cells. J Neurosci 30, 4667-4675 https://doi.org/10.1523/JNEUROSCI.4255-09.2010
- Cunningham M, Cho JH, Leung A et al (2014) hPSC-derived maturing GABAergic interneurons ameliorate seizures and abnormal behavior in epileptic mice. Cell Stem Cell 15, 559-573 https://doi.org/10.1016/j.stem.2014.10.006
- Joseph NM and Morrison SJ (2005) Toward an understanding of the physiological function of Mammalian stem cells. Dev Cell 9, 173-183 https://doi.org/10.1016/j.devcel.2005.07.001
- Saha K and Jaenisch R (2009) Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 5, 584-595 https://doi.org/10.1016/j.stem.2009.11.009
- Li H, Jiang H, Zhang B and Feng J (2018) Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells. J Parkinsons Dis 8, 479-493 https://doi.org/10.3233/JPD-181353
- Sison SL, Vermilyea SC, Emborg ME and Ebert AD (2018) Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes. Curr Neurol Neurosci Rep 18, 84 https://doi.org/10.1007/s11910-018-0893-8
- Ueda K, Fukushima H, Masliah E et al (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90, 11282-11286 https://doi.org/10.1073/pnas.90.23.11282
- Weinreb PH, Zhen W, Poon AW, Conway KA and Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715 https://doi.org/10.1021/bi961799n
- Davidson WS, Jonas A, Clayton DF and George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273, 9443-9449 https://doi.org/10.1074/jbc.273.16.9443
- Bartels T, Choi JG and Selkoe DJ (2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110 https://doi.org/10.1038/nature10324
- Wang W, Perovic I, Chittuluru J et al (2011) A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A 108, 17797-17802 https://doi.org/10.1073/pnas.1113260108
- Dettmer U, Newman AJ, Soldner F et al (2015) Parkinsoncausing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun 6, 7314 https://doi.org/10.1038/ncomms8314
- Tong J, Wong H, Guttman M et al (2010) Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 133, 172-188 https://doi.org/10.1093/brain/awp282
- Winklhofer KF, Tatzelt J and Haass C (2008) The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27, 336-349 https://doi.org/10.1038/sj.emboj.7601930
- McCann H, Stevens CH, Cartwright H and Halliday GM (2014) alpha-Synucleinopathy phenotypes. Parkinsonism Relat Disord 20 Suppl 1, S62-67 https://doi.org/10.1016/S1353-8020(13)70017-8
- Savica R, Grossardt BR, Bower JH, Ahlskog JE and Rocca WA (2013) Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol 70, 859-866 https://doi.org/10.1001/jamaneurol.2013.114
- Oueslati A, Fournier M and Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 183, 115-145 https://doi.org/10.1016/S0079-6123(10)83007-9
- Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739-29752 https://doi.org/10.1074/jbc.M600933200
- Chen L and Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8, 657-663 https://doi.org/10.1038/nn1443
- Yamada M, Iwatsubo T, Mizuno Y and Mochizuki H (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91, 451-461 https://doi.org/10.1111/j.1471-4159.2004.02728.x
- Takahashi M, Kanuka H, Fujiwara H et al (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett 336, 155-158 https://doi.org/10.1016/S0304-3940(02)01258-2
- Oueslati A (2016) Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? J Parkinsons Dis 6, 39-51 https://doi.org/10.3233/JPD-160779
- Tenreiro S, Eckermann K and Outeiro TF (2014) Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci 7, 42 https://doi.org/10.3389/fnmol.2014.00042
- Arenas E, Denham M and Villaescusa JC (2015) How to make a midbrain dopaminergic neuron. Development 142, 1918-1936 https://doi.org/10.1242/dev.097394
- Park CH, Minn YK, Lee JY et al (2005) In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem 92, 1265-1276 https://doi.org/10.1111/j.1471-4159.2004.03006.x
- Zeng X, Cai J, Chen J et al (2004) Dopaminergic differentiation of human embryonic stem cells. Stem Cells 22, 925-940 https://doi.org/10.1634/stemcells.22-6-925
- Perrier AL, Tabar V, Barberi T et al (2004) Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A 101, 12543-12548 https://doi.org/10.1073/pnas.0404700101
- Sonntag KC, Pruszak J, Yoshizaki T, van Arensbergen J, Sanchez-Pernaute R and Isacson O (2007) Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 25, 411-418 https://doi.org/10.1634/stemcells.2006-0380
- Roy NS, Cleren C, Singh SK, Yang L, Beal MF and Goldman SA (2006) Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12, 1259-1268 https://doi.org/10.1038/nm1495
- Kim BK, Kim SE, Shim JH et al (2006) Neurogenic effect of vascular endothelial growth factor during germ layer formation of human embryonic stem cells. FEBS Lett 580, 5869-5874 https://doi.org/10.1016/j.febslet.2006.09.053
- Swistowski A, Peng J, Han Y, Swistowska AM, Rao MS and Zeng X (2009) Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them. PLoS One 4, e6233 https://doi.org/10.1371/journal.pone.0006233
- Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M and Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27, 275-280 https://doi.org/10.1038/nbt.1529
- Fasano CA, Chambers SM, Lee G, Tomishima MJ and Studer L (2010) Efficient derivation of functional floor plate tissue from human embryonic stem cells. Cell Stem Cell 6, 336-347 https://doi.org/10.1016/j.stem.2010.03.001
- Kriks S, Shim JW, Piao J et al (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547-551 https://doi.org/10.1038/nature10648
- Chambers SM, Qi Y, Mica Y et al (2012) Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat Biotechnol 30, 715-720 https://doi.org/10.1038/nbt.2249
- Soldner F, Hockemeyer D, Beard C et al (2009) Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-977 https://doi.org/10.1016/j.cell.2009.02.013
- Baba M, Nakajo S, Tu PH et al (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152, 879-884
- Mazzulli JR, Zunke F, Isacson O, Studer L and Krainc D (2016) alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A 113, 1931-1936 https://doi.org/10.1073/pnas.1520335113
- Giasson BI, Duda JE, Murray IV et al (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985-989 https://doi.org/10.1126/science.290.5493.985
- Lin L, Goke J, Cukuroglu E, Dranias MR, VanDongen AM and Stanton LW (2016) Molecular Features Underlying Neurodegeneration Identified through In Vitro Modeling of Genetically Diverse Parkinson's Disease Patients. Cell Rep 15, 2411-2426 https://doi.org/10.1016/j.celrep.2016.05.022
- Kouroupi G, Taoufik E, Vlachos IS et al (2017) Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease. Proc Natl Acad Sci U S A 114, E3679-E3688 https://doi.org/10.1073/pnas.1617259114
- Ryan SD, Dolatabadi N, Chan SF et al (2013) Isogenic human iPSC Parkinson's model shows nitrosative stressinduced dysfunction in MEF2-PGC1alpha transcription. Cell 155, 1351-1364 https://doi.org/10.1016/j.cell.2013.11.009
- Mazzulli JR, Zunke F, Tsunemi T et al (2016) Activation of beta-Glucocerebrosidase Reduces Pathological alpha-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. J Neurosci 36, 7693-7706 https://doi.org/10.1523/JNEUROSCI.0628-16.2016
- Prots I, Grosch J, Brazdis RM et al (2018) alpha-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proc Natl Acad Sci U S A 115, 7813-7818 https://doi.org/10.1073/pnas.1713129115
- Ludtmann MHR, Angelova PR, Horrocks MH et al (2018) alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease. Nat Commun 9, 2293 https://doi.org/10.1038/s41467-018-04422-2
- Tagliafierro L, Zamora ME and Chiba-Falek O (2019) Multiplication of the SNCA locus exacerbates neuronal nuclear aging. Hum Mol Genet 28, 407-421 https://doi.org/10.1093/hmg/ddy355
- Klein C and Westenberger A (2012) Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2, a008888 https://doi.org/10.1101/cshperspect.a008888
- di Domenico A, Carola G, Calatayud C et al (2019) Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease. Stem Cell Reports 12, 213-229 https://doi.org/10.1016/j.stemcr.2018.12.011
- Shaltouki A, Sivapatham R, Pei Y et al (2015) Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Reports 4, 847-859 https://doi.org/10.1016/j.stemcr.2015.02.019
- Chung SY, Kishinevsky S, Mazzulli JR et al (2016) Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and alpha- Synuclein Accumulation. Stem Cell Reports 7, 664-677 https://doi.org/10.1016/j.stemcr.2016.08.012
- Hruska KS, LaMarca ME, Scott CR and Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29, 567-583 https://doi.org/10.1002/humu.20676
- Nalls MA, Duran R, Lopez G et al (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 70, 727-735 https://doi.org/10.1001/jamaneurol.2013.1925
- Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361, 1651-1661 https://doi.org/10.1056/NEJMoa0901281
- Eblan MJ, Walker JM and Sidransky E (2005) The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 352, 728-731; author reply 728-731 https://doi.org/10.1056/NEJM200502173520719
- Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A and Sidransky E (2004) Parkinsonism among Gaucher disease carriers. J Med Genet 41, 937-940 https://doi.org/10.1136/jmg.2004.024455
- Halperin A, Elstein D and Zimran A (2006) Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 36, 426-428 https://doi.org/10.1016/j.bcmd.2006.02.004
- Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME and Sidransky E (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 81, 70-73 https://doi.org/10.1016/j.ymgme.2003.11.004
- Kim S, Yun SP, Lee S et al (2018) GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 115, 798-803 https://doi.org/10.1073/pnas.1700465115
- Luk KC, Song C, O'Brien P et al (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 106, 20051-20056 https://doi.org/10.1073/pnas.0908005106
- Soria-Valles C and Lopez-Otin C (2016) iPSCs: On the Road to Reprogramming Aging. Trends Mol Med 22, 713-724 https://doi.org/10.1016/j.molmed.2016.05.010
- Zeltner N and Studer L (2015) Pluripotent stem cell-based disease modeling: current hurdles and future promise. Curr Opin Cell Biol 37, 102-110 https://doi.org/10.1016/j.ceb.2015.10.008
- Vera E and Studer L (2015) When rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease. Development 142, 3085-3089 https://doi.org/10.1242/dev.120667
- Studer L, Vera E and Cornacchia D (2015) Programming and Reprogramming Cellular Age in the Era of Induced Pluripotency. Cell Stem Cell 16, 591-600 https://doi.org/10.1016/j.stem.2015.05.004
- Miller JD, Ganat YM, Kishinevsky S et al (2013) Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13, 691-705 https://doi.org/10.1016/j.stem.2013.11.006
- Bolognin S, Fossepre M, Qing X et al (2019) 3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. Adv Sci (Weinh) 6, 1800927 https://doi.org/10.1002/advs.201800927
- Jo J, Xiao Y, Sun AX et al (2016) Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. Cell Stem Cell 19, 248-257 https://doi.org/10.1016/j.stem.2016.07.005
- Monzel AS, Smits LM, Hemmer K et al (2017) Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells. Stem Cell Reports 8, 1144-1154 https://doi.org/10.1016/j.stemcr.2017.03.010
- Peng J, Oo ML and Andersen JK (2010) Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. J Neurochem 115, 1363-1373 https://doi.org/10.1111/j.1471-4159.2010.07036.x
- Havlicek S, Kohl Z, Mishra HK et al (2014) Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients' neurons. Hum Mol Genet 23, 2527-2541 https://doi.org/10.1093/hmg/ddt644
- Tagliafierro L, Glenn OC, Zamora ME et al (2017) Genetic analysis of alpha-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies. Alzheimers Dement 13, 1237-1250 https://doi.org/10.1016/j.jalz.2017.03.001
- Hu Y, Qu ZY, Cao SY et al (2016) Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. J Neurosci Methods 266, 42-49 https://doi.org/10.1016/j.jneumeth.2016.03.017
- Crompton LA, Byrne ML, Taylor H et al (2013) Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. Stem Cell Res 11, 1206-1221 https://doi.org/10.1016/j.scr.2013.08.002
- Serio A, Bilican B, Barmada SJ et al (2013) Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A 110, 4697-4702 https://doi.org/10.1073/pnas.1300398110